A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Many tumors depend on MAPK/ERK signaling to sustain growth, avoid cell death, and metastasize. We show that specific and clinically relevant MAPK/ERK signaling inhibitors can be discovered in vivo with a high-throughput screening pipeline in small animals.
Authors
- Szymon Gorgoń (ORCID: https://orcid.org/0000-0002-4340-7316)
- Ola Billing (ORCID: https://orcid.org/0000-0001-5824-6263)
- Oskar Hemmingsson (ORCID: https://orcid.org/0000-0003-1732-168X)
- Anna U. Eriksson
Institutions
- Umeå University (SE)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0221
- Citations
- 3
- Primary Topic
- Genetics, Aging, and Longevity in Model Organisms
- Type
- article
- Field-Weighted Citation Impact
- 0.68
Funders
- Wenner-Gren Stiftelserna
- Västerbotten Läns Landsting
- Knut och Alice Wallenbergs Stiftelse
- Cancer Research Foundation in Northern Sweden
- National Institutes of Health